TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: To Evaluate the Impact of Three Feeding Regimens on the Recovery of Children From Uncomplicated Severe Acute Malnutrition (SAM) in India and to Use the Evidence to Inform National Policy
Brief Summary: This project aims to assess the efficacy of three options under consideration in India for home management of Severe Acute Malnutrition (SAM). The investigators propose to conduct a multi-center randomized controlled trial to determine the efficacy of two community-supported home-based regimes using centrally or locally produced Ready to Use Therapeutic Foods (RUTF) for recovery from uncomplicated SAM after 16 weeks of management, compared with an augmented home-prepared foods regimen. The trial will enroll 911 children with uncomplicated SAM and will have enough statistical power to detect a 15% or greater difference in recovery rates between either one of the intervention groups compared with comparison group.


Options:
A: Arm Label: Antiretroviral Therapy; Type: EXPERIMENTAL; Interventions: Drug: Raltegravir | Arm Label: Opportunistic Infection (OI) Prophylaxis; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Azithromycin, Drug: Albendazole, Drug: Isoniazid | Arm Label: Nutritional Support; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ready to Use Supplementary Food | Intervention Type: DRUG; Name: Raltegravir; Assigned to Arm(s): Antiretroviral Therapy | Intervention Type: DRUG; Name: Fluconazole; Assigned to Arm(s): Opportunistic Infection (OI) Prophylaxis | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Opportunistic Infection (OI) Prophylaxis | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Opportunistic Infection (OI) Prophylaxis | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): Opportunistic Infection (OI) Prophylaxis | Intervention Type: DIETARY_SUPPLEMENT; Name: Ready to Use Supplementary Food; Assigned to Arm(s): Nutritional Support
B: Arm Label: RUTF-Centrally produced; Type: EXPERIMENTAL; Interventions: Other: Ready to Use Therapeutic Food-Centrally produced | Arm Label: RUTF-Locally produced; Type: EXPERIMENTAL; Interventions: Other: Ready to Use Therapeutic Food-Locally produced | Arm Label: High energy and micronutrient rich foods; Type: ACTIVE_COMPARATOR; Interventions: Other: High energy and micronutrient rich foods | Intervention Type: OTHER; Name: Ready to Use Therapeutic Food-Centrally produced; Assigned to Arm(s): RUTF-Centrally produced | Intervention Type: OTHER; Name: Ready to Use Therapeutic Food-Locally produced; Assigned to Arm(s): RUTF-Locally produced | Intervention Type: OTHER; Name: High energy and micronutrient rich foods; Assigned to Arm(s): High energy and micronutrient rich foods
C: Intervention Type: DIETARY_SUPPLEMENT; Name: PlumpyNut; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: PlumpyDoz; Assigned to Arm(s): N/A
D: Intervention Type: DIETARY_SUPPLEMENT; Name: fortified spread (RUTF); Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: maize and soy flour; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-month, Open Label, Randomised, Effectiveness Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler Compared With Usual Maintenance Therapy in Subjects With Asthma
Brief Summary: This study is designed to compare the effectiveness and safety of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444) or 200mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444) ) delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with the existing asthma maintenance therapy over twelve months in subjects diagnosed with asthma. This is a Phase III multi-centre, randomised open label study. Subjects who meet the eligibility criteria are randomised and will enter a 12 month treatment period.


Options:
A: Arm Label: GW642444M/lactose; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: GW642444, Drug: Magnesium Stearate | Arm Label: GW642444M/MgSt; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: GW642444, Drug: Magnesium Stearate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: GW642444, Drug: Magnesium Stearate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): GW642444M/MgSt, GW642444M/lactose, Placebo | Intervention Type: DRUG; Name: GW642444; Assigned to Arm(s): GW642444M/MgSt, GW642444M/lactose, Placebo | Intervention Type: DRUG; Name: Magnesium Stearate; Assigned to Arm(s): GW642444M/MgSt, GW642444M/lactose, Placebo
B: Arm Label: Arm 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Arm 1
C: Arm Label: FF/VI; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate + vilanterol, Drug: inhaled corticosteroid with or without a long acting beta2-agonist | Arm Label: ICS or ICS/LABA maintenance therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: inhaled corticosteroid with or without a long acting beta2-agonist | Intervention Type: DRUG; Name: fluticasone furoate + vilanterol; Assigned to Arm(s): FF/VI | Intervention Type: DRUG; Name: inhaled corticosteroid with or without a long acting beta2-agonist; Assigned to Arm(s): FF/VI, ICS or ICS/LABA maintenance therapy
D: Arm Label: Fluticasone furoate/GW642444; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/GW642444 | Arm Label: Fluticasone propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate | Intervention Type: DRUG; Name: Fluticasone Furoate/GW642444; Assigned to Arm(s): Fluticasone furoate/GW642444 | Intervention Type: DRUG; Name: Fluticasone propionate; Assigned to Arm(s): Fluticasone propionate

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-month, Open Label, Randomised, Effectiveness Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler Compared With Usual Maintenance Therapy in Subjects With Asthma
Brief Summary: This study is designed to compare the effectiveness and safety of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444) or 200mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444) ) delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with the existing asthma maintenance therapy over twelve months in subjects diagnosed with asthma. This is a Phase III multi-centre, randomised open label study. Subjects who meet the eligibility criteria are randomised and will enter a 12 month treatment period.


Options:
A: Arm Label: FF/VI; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate + vilanterol, Drug: inhaled corticosteroid with or without a long acting beta2-agonist | Arm Label: ICS or ICS/LABA maintenance therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: inhaled corticosteroid with or without a long acting beta2-agonist | Intervention Type: DRUG; Name: fluticasone furoate + vilanterol; Assigned to Arm(s): FF/VI | Intervention Type: DRUG; Name: inhaled corticosteroid with or without a long acting beta2-agonist; Assigned to Arm(s): FF/VI, ICS or ICS/LABA maintenance therapy
B: Arm Label: Fluticasone Furoate (FF); Type: ACTIVE_COMPARATOR; Interventions: Drug: FF | Arm Label: Fluticasone Furoate /Vilanterol (VI); Type: ACTIVE_COMPARATOR; Interventions: Drug: FF/VI | Arm Label: Fluticasone Furoate/GSK573719; Type: EXPERIMENTAL; Interventions: Drug: FF/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF; Assigned to Arm(s): Fluticasone Furoate (FF) | Intervention Type: DRUG; Name: FF/VI; Assigned to Arm(s): Fluticasone Furoate /Vilanterol (VI)
C: Intervention Type: DRUG; Name: FLUTIFORM® (Formoterol fumarate / Fluticasone propionate); Assigned to Arm(s): N/A
D: Arm Label: QMF149 Twisthaler® 500/400; Type: EXPERIMENTAL; Interventions: Drug: QMF149 Twisthaler® | Arm Label: Mometasone Twisthaler®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mometasone Twisthaler® | Intervention Type: DRUG; Name: QMF149 Twisthaler®; Assigned to Arm(s): QMF149 Twisthaler® 500/400 | Intervention Type: DRUG; Name: Mometasone Twisthaler®; Assigned to Arm(s): Mometasone Twisthaler®

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Calcineurin inhibitors, such as cyclosporine and tacrolimus, have improved allograft survival in kidney organ transplantation. Indeed, they have reduced the incidence of acute rejection episodes of cadaveric allograft recipients. Although marked progression has been made in initial survival rates, long-term kidney graft survival has yet to show such encouraging results. Because CNIs are associated with adverse effects, particularly nephrotoxicity, which contribute to declining organ function and eventual graft loss. In kidney transplants, progressive allograft dysfunction has been shown to develop in as many as 94% of patients by 1 year.

Therefore, reducing or eliminating the dose of CNIs to minimize nephrotoxicity must be balanced against the maintenance of adequate immunosuppression.

Certican allows CNI dose reduction then provides renal function improvement and current PSI strategy point out that early intervention is important in managing the risk of CAN before it develops in both de novo and maintenance renal transplant recipients.

To demonstrate Certican early introduction after 1 month provides better renal function with no change of efficacy compared to standard regimen, and also prevent delayed wound healing.


Options:
A: Arm Label: Everolimus + Low dose CsA +PD; Type: EXPERIMENTAL; Interventions: Drug: Everolimus + Low dose CsA +PD | Arm Label: Myfortic+ Standard CsA + PD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Myfortic+ Standard CsA + PD | Intervention Type: DRUG; Name: Everolimus + Low dose CsA +PD; Assigned to Arm(s): Everolimus + Low dose CsA +PD | Intervention Type: DRUG; Name: Myfortic+ Standard CsA + PD; Assigned to Arm(s): Myfortic+ Standard CsA + PD
B: Intervention Type: DRUG; Name: daclizumab; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclosporine; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: AUC monitored withdrawal of MMF or CNI | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: AUC monitored withdrawal of MMF or CNI | Intervention Type: DRUG; Name: AUC monitored withdrawal of MMF or CNI; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Brief Summary: The purpose of this study is to evaluate the safety of long-term ivacaftor treatment in participants with cystic fibrosis (CF) from Studies 110 (NCT01614457), 111 (NCT01614470), and 113 (NCT01685801).


Options:
A: Arm Label: Ivacaftor; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Arm Label: Observational; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Ivacaftor
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg Ivacaftor q12h; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): 150 mg Ivacaftor q12h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Part A: 3 to <24 months; Type: EXPERIMENTAL; Interventions: Drug: IVA | Arm Label: Part B + A/B:1 to < 24 months; Type: EXPERIMENTAL; Interventions: Drug: IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): Part A: 3 to <24 months, Part B + A/B:1 to < 24 months
D: Arm Label: Treatment Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor, Drug: Placebo | Arm Label: Treatment Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor, Drug: Placebo | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Treatment Sequence 1, Treatment Sequence 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Treatment Sequence 1, Treatment Sequence 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Electroacupuncture for Persistent Insomnia Symptoms Associated With Major Depressive Disorder
Brief Summary: The purpose of this study is to evaluate the clinical effectiveness of acupuncture treatment on residual insomnia in major depressive patients.


Options:
A: Arm Label: stress management, acupressure; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: pressure pain sensitivity measure followed bu acupressure | Arm Label: bio feedback guided, stress management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: pressure pain sensitivity measure followed bu acupressure; Assigned to Arm(s): stress management, acupressure
B: Arm Label: Traditional Acupuncture; Type: EXPERIMENTAL; Interventions: Other: Acupuncture | Arm Label: Minimal Acupuncture; Type: ACTIVE_COMPARATOR; Interventions: Other: Acupuncture | Arm Label: Placebo Acupuncture; Type: PLACEBO_COMPARATOR; Interventions: Other: Acupuncture | Intervention Type: OTHER; Name: Acupuncture; Assigned to Arm(s): Minimal Acupuncture, Placebo Acupuncture, Traditional Acupuncture
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Electroacupuncture | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Sham | Intervention Type: PROCEDURE; Name: Electroacupuncture; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Sham; Assigned to Arm(s): 2
D: Arm Label: Traditional Acupuncture; Type: EXPERIMENTAL; Interventions: Other: Acupuncture | Arm Label: Minimal Acupuncture; Type: ACTIVE_COMPARATOR; Interventions: Other: Acupuncture | Arm Label: Placebo Acupuncture; Type: PLACEBO_COMPARATOR; Interventions: Other: Acupuncture | Intervention Type: OTHER; Name: Acupuncture; Assigned to Arm(s): Minimal Acupuncture, Placebo Acupuncture, Traditional Acupuncture

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Chinese Bayberry Juice on Liver Enzymes and Plasma Antioxidant Activity in Adult Subjects With Features of Fatty Liver Disease: a Randomised Placebo-controlled Trial
Brief Summary: Chinese bayberry, one of six Myrica species native to China, is rich in anthocyanins, and cyanidin-3-O-glucoside (C3G) was identified as a major anthocyanin component. In previous animal studies from us and other investigators, anthocyanins have been shown to ameliorate dyslipidemia and hepatic steatosis in different rodent models. The aim of the present study was to examine the effects of Chinese bayberry juice (CBJ) on the serum lipid profile and on levels of biomarkers related to antioxidant status in young adults with features of fatty liver disease.


Options:
A: Arm Label: TREATED GROUP; Type: EXPERIMENTAL; Interventions: Drug: Hydroxytyrosol plus Vitamin E | Arm Label: PLACEBO GROUP; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hydroxytyrosol plus Vitamin E; Assigned to Arm(s): TREATED GROUP | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLACEBO GROUP
B: Arm Label: Omega 3 recipient arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega 3 Fish Oil supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega 3 Fish Oil supplements; Assigned to Arm(s): Omega 3 recipient arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Chinese bayberry juice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Chinese bayberry juice | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Chinese bayberry juice; Assigned to Arm(s): Chinese bayberry juice | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: DHA250; Type: EXPERIMENTAL; Interventions: Drug: DHA250, Behavioral: Lifestyle intervention | Arm Label: DHA500; Type: EXPERIMENTAL; Interventions: Drug: DHA500, Behavioral: Lifestyle intervention | Arm Label: PLA; Type: PLACEBO_COMPARATOR; Interventions: Drug: PLACEBO, Behavioral: Lifestyle intervention | Intervention Type: DRUG; Name: DHA250; Assigned to Arm(s): DHA250 | Intervention Type: DRUG; Name: DHA500; Assigned to Arm(s): DHA500 | Intervention Type: DRUG; Name: PLACEBO; Assigned to Arm(s): PLA | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): DHA250, DHA500, PLA

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Brief Summary: This is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by active treatment, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod in participants with RRMS. The study has 2 periods: Period 1, the double-blind, placebo-controlled period (up to 24 months) and Period 2, the active treatment period (24 months).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: rituximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): 1
B: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: normal saline | Arm Label: Baseline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab | Intervention Type: OTHER; Name: normal saline; Assigned to Arm(s): Placebo
C: Arm Label: Natalizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Natalizumab | Arm Label: Interferon-beta-1b; Type: EXPERIMENTAL; Interventions: Drug: interferon beta-1b | Intervention Type: DRUG; Name: interferon beta-1b; Assigned to Arm(s): Interferon-beta-1b | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Natalizumab
D: Arm Label: Placebo-Controlled Phase: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo-Controlled Phase: Laquinimod 0.6 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod, Drug: Placebo | Arm Label: Placebo-Controlled Phase: Laquinimod 1.2 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Arm Label: Active Treatment Phase: Laquinimod 0.6 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod, Drug: Placebo | Arm Label: Active Treatment Phase: Laquinimod 1.2 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Arm Label: Active Treatment Phase: Off Drug; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Laquinimod; Assigned to Arm(s): Active Treatment Phase: Laquinimod 0.6 mg, Active Treatment Phase: Laquinimod 1.2 mg, Placebo-Controlled Phase: Laquinimod 0.6 mg, Placebo-Controlled Phase: Laquinimod 1.2 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Active Treatment Phase: Laquinimod 0.6 mg, Placebo-Controlled Phase: Laquinimod 0.6 mg, Placebo-Controlled Phase: Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: From Evidence-Base to Practice: Implementing RDAD in AAA Community-Based Services
Brief Summary: The University of Washington's Northwest Research Group on Aging is partnering with Area Agencies on Aging (AAA) in Washington and Oregon to complete this translational investigation of RDAD (Reducing Disabilities in Alzheimer's Disease). RDAD is an evidence-based program with demonstrated efficacy in helping older adults with dementia maintain physical function and remain physically and mentally healthy. This study asks two questions: 1) Can AAA partners successfully translate and implement RDAD, and 2) Is AAA implementation of RDAD effective in producing desired outcomes among agencies, providers, and older adults with dementia and their family members. This study is being conducted in Washington and Oregon states.


Options:
A: Arm Label: Psychological treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Psychological treatment | Arm Label: Cognitive training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive training | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychological treatment; Assigned to Arm(s): Psychological treatment | Intervention Type: BEHAVIORAL; Name: Cognitive training; Assigned to Arm(s): Cognitive training
B: Arm Label: RDAD; Type: OTHER; Interventions: Behavioral: RDAD | Intervention Type: BEHAVIORAL; Name: RDAD; Assigned to Arm(s): RDAD
C: Arm Label: Problem Solving Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Problem Solving Therapy | Arm Label: Problem Solving Therapy + Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Problem Solving Therapy + Exercise | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced Usual Care | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): Problem Solving Therapy | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy + Exercise; Assigned to Arm(s): Problem Solving Therapy + Exercise | Intervention Type: OTHER; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to interest | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to function | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to both interest and function | Arm Label: 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Activity matched to interest; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Activity matched to function; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Activity matched to both interest and function; Assigned to Arm(s): 3

Answer: B